FamicordtxS.A.
Research and experimental development in natural sciences and engineering
Overview
Famicordtx is a biotech company focused on developing cell and gene therapies, specifically working on creating the world's first CAR-T cancer therapy based on an allogeneic populational bank. They aim to provide advanced immunotherapy for patients with hematological cancers by using genetically modified T lymphocytes. The company operates under stringent GMP standards for drug manufacturing and collaborates with global scientists and clinicians.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2019-08-26. Active
46 1020 1026 0000 1102 0392 8942- 36 1020 1026 0000 1502 0392 8926
- 36 1020 1026 0000 1802 0392 8876
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Dec 28, 2023 | Aid for research and development projects: experimental development | –– | Prezes Agencji Badań Medycznych | |
| Dec 28, 2023 | Aid for research and development projects: industrial research | –– | Prezes Agencji Badań Medycznych | |
| Dec 28, 2023 | Aid for research and development projects: fundamental research | –– | Prezes Agencji Badań Medycznych |
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
If the management board is a multi-member management board, two members of the management board acting jointly, or one member of the management board acting jointly with a commercial proxy, or a commercial proxy acting jointly with a member of the management board, are authorized to make declarations of will and sign on behalf of the company.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Scope FluidicsS.A. | $1,264,188.85 | scopefluidics.com | ||
| WPD Pharmaceuticalssp. z o.o. | $919,175.63 | wpdpharmaceuticals.com | ||
| BioceltixS.A. | $616,315.97 | bioceltix.com | ||
| OrthogetS.A. | $532,980.53 | orthoget.com | ||
| CTI Clinical Trial and Consulting Services Polandsp. z o.o. | $527,145.56 | ctifacts.com | ||
| VET Cell Techsp. z o.o. | $483,439.81 | vetcelltech.com | ||
| BiottsS.A. | $372,115.60 | biotts.com | ||
| Medicofarma BiotechS.A. | $314,882.33 | medicofarmabiotech.pl | ||
| MultiqureS.A. | $284,781.52 | purebiologics.com | ||
| Frontline BiosciencesS.A. | $219,186.29 | frontlinebiosciences.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-05-13 | Share capital change (140,200.00 PLN → 528,200.00 PLN) | |
| 2024-09-23 | Share capital change (139,412.00 PLN → 140,200.00 PLN) | |
| 2022-03-10 | Share capital change (110,412.00 PLN → 139,412.00 PLN) | |
| 2021-10-01 | Share capital change (100,000.00 PLN → 110,412.00 PLN) | |
| 2019-08-14 | Entered in the register |
FAQ
Last updated: 2026-10-12